Care report and literature analysis of exogenous insulin autoimmune syndrome
- VernacularTitle:外源性胰岛素自身免疫综合征的个案报道及文献分析
- Author:
Yujuan WANG
1
,
2
;
Quanzhi LI
3
;
Jing WANG
4
;
Mengyuan ZHU
1
,
2
;
Xiaofei HAO
1
,
2
;
Jie CHENG
1
Author Information
1. Dept. of Pharmacy，Hebei Provincial Hospital of Traditional Chinese Medicine，Shijiazhuang 050011，China
2. Key Laboratory of Evaluation and Transformation of Traditional Chinese Medicine Under Hebei Provincial Administration of Traditional Chinese Medicine，Shijiazhuang 050011，China
3. Dept. of Pharmacy，Beijing Jishuitan Hospital of Capital Medical University，Beijing 100035，China
4. Dept. of Endocrinology，Hebei Provincial Hospital of Traditional Chinese Medicine，Shijiazhuang 050011，China
- Publication Type:Journal Article
- Keywords:
insulin autoimmune syndrome;
lipoic acid;
insulin;
hypoglycemia
- From:
China Pharmacy
2025;36(15):1921-1925
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the significance of pharmaceutical care through the diagnosis and treatment of a patient with exogenous insulin autoimmune syndrome （EIAS）， combined with the analysis of literature reports. METHODS Clinical pharmacist participated in the diagnosis and treatment process of one case of EIAS. Based on the characteristics of the patient’s condition， the pharmacist provided medication suggestions and formulated pharmaceutical monitoring measures. At the same time， the pharmacist searched for relevant literature on insulin autoimmune syndrome （IAS） and EIAS， extracted data （gender， age， occurrence time， laboratory tests， clinical symptoms， intervention and outcome）， and conducted analysis. RESULTS Based on the patient’s medication information in the past 3 years， clinical pharmacist determined that the EIAS was likely caused by insulin aspartate 30. The clinician adopted the clinical pharmacist’s suggestion to discontinue insulin and switch to oral hypoglycemic drugs. The patient improved after treatment. The literature analysis showed that among the 257 patients with IAS reported， 212 cases were caused by drugs； among them， 23 cases were caused by lipoic acid， and 56 cases were caused by exogenous insulin. There were no significant differences in age， glycosylated hemoglobin， and body mass index between the two groups. The lowest blood glucose level in the lipoic acid group was significantly lower than that in the exogenous insulin group （P＜0.05）. The proportion of females and the proportion of fasting insulin ≥ 1 000 μU/mL were significantly higher in the lipoic acid group than in the exogenous insulin group （P＜0.05）. CONCLUSIONS Compared with EIAS， lipoic acid-induced IAS usually causes more severe hypoglycemia， and the fasting insulin level is usually higher than 1 000 μU/mL， which is more common in female patients. The participation of clinical pharmacists in the diagnosis and treatment of EIAS can help improve the diagnosis and treatment level of similar rare diseases and ensure the safety of patients’ medication.
